Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

This study has been completed.
Sponsor:
Information provided by:
Anacor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00680160
First received: May 15, 2008
Last updated: NA
Last verified: May 2008
History: No changes posted
  Purpose

The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25 otherwise healthy adult patients with onychomycosis.


Condition Intervention Phase
Onychomycosis
Drug: AN2690
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis

Resource links provided by NLM:


Further study details as provided by Anacor Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Efficacy measures of linear toenail growth, fungal culture results, KOH results, and clear toenail [ Time Frame: Days 0, 14, 28, 42, 84, 120, 150, 180, 240, 300, and 360 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerance assessed by application site reactions, adverse events, laboratory tests, vital signs, physical examinations, and 12-lead EKG [ Time Frame: Days 0-28, 42, 84, 120, 150, 180, 240, 300, and 360 ] [ Designated as safety issue: Yes ]

Enrollment: 15
Study Start Date: April 2006
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: AN2690
    AN2690 7.5% Solution, once daily for 28 days
Detailed Description:

For this study, the case definition of onychomycosis included moderate to severe distal subungual onychomycosis including subjects with evidence of subungual dermatophytoma or yellow spikes, lateral and proximal onychomycosis and severely dystrophic nail plates. Subjects with only superficial white onychomycosis were excluded. Confirmation of the clinical diagnosis of onychomycosis of at least one great toenail included a positive KOH wet mount.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A witnessed, signed informed consent approved by Institutional Review Board
  • Male or female of any race at least 18 years of age but not older than 65 years of age at the time of screening
  • Body Mass Index between 18.5 and 35, inclusive
  • Onychomycosis involving > 80% of both great toenails, as determined by visual inspection after the nail has been trimmed
  • Each great toenail possess a combined thickness of the nail plate and nail bed > 3 mm
  • At least six additional toenails with clinical diagnosis of onychomycosis
  • A positive KOH wet mount for at least one great toenail
  • If subject is a female of childbearing potential, must be using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study
  • Considered reliable and capable of understanding his/her responsibility and role in the study

Exclusion Criteria:

  • History of allergy to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
  • Clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety
  • Diabetes mellitus requiring treatment other than diet and exercise
  • Unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study
  • Nursing, pregnant or planning to become pregnant during the study
  • Has not undergone the specified washout period(s) for the following topical preparations or does the subject require the concurrent use of any of the following topical medications:

    1. Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study: 4 weeks
    2. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
  • Has not undergone the specified washout period(s) for the following systemic medications or does the subject require the concurrent use of any of the following systemic medications:

    1. Corticosteroids (including intramuscular injections): 2 weeks
    2. Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophyte: 24 weeks
    3. Systemic immunomodulators: 4 weeks
  • Received treatment of any type for cancer within the last 6 months
  • History of any significant internal disease
  • Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
  • AIDS or AIDS related complex
  • History of street drug or alcohol abuse
  • Donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation
  • Donated plasma during the two week period preceding study initiation
  • Participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00680160

Locations
United States, Texas
J&S Studies
Bryan, Texas, United States, 77802
Sponsors and Collaborators
Anacor Pharmaceuticals, Inc.
Investigators
Study Director: Karl Beutner, MD, PhD Anacor Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Karl Beutner, MD, PhD, Chief Medical Officer, Anacor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00680160     History of Changes
Other Study ID Numbers: AN2690-ONYC-202
Study First Received: May 15, 2008
Last Updated: May 15, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Anacor Pharmaceuticals, Inc.:
Onychomycosis
Fungal Nail

Additional relevant MeSH terms:
Onychomycosis
Tinea
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Nail Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 26, 2014